LaseMD System for the Treatment of Melasma

NAActive, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 7, 2018

Primary Completion Date

May 31, 2019

Study Completion Date

June 30, 2019

Conditions
Melasma
Interventions
DEVICE

LaseMD System

A non-invasive fractional thulium laser delivering a wavelength of light energy as a fractionated array of microbeams to be absorbed by and damage the target molecule, a chromophore.

Trial Locations (1)

10016

Laser and Skin Surgery Center of New York, New York

Sponsors
All Listed Sponsors
lead

LUTRONIC Corporation

INDUSTRY